Somewhat Positive News Coverage Somewhat Unlikely to Impact Aratana Therapeutics (PETX) Stock Price
News coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.0551868616242 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Aratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma Therapeutic (streetinsider.com)
- Aratana Therapeutics, Inc. (NASDAQ:PETX) – Is the Stock Safe to Invest? – Nasdaq Journal (press release) (nasdaqjournal.com)
- Aratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma Therapeutic – StreetInsider.com (streetinsider.com)
- Aratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- Aratana nears approval for canine cancer vaccine (bizjournals.com)
Several analysts have issued reports on PETX shares. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus restated a “hold” rating and set a $6.00 price objective on shares of Aratana Therapeutics in a research note on Monday, December 18th. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. Jefferies Group set a $9.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 16th. Finally, ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $8.55.
Aratana Therapeutics (NASDAQ:PETX) opened at $5.40 on Friday. The company has a market capitalization of $234.81, a price-to-earnings ratio of -3.72 and a beta of 3.36. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $8.63. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42.
Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company’s revenue was up 1440.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) EPS. equities analysts forecast that Aratana Therapeutics will post -1.03 earnings per share for the current year.
In related news, COO Brent Standridge sold 10,000 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the sale, the chief operating officer now owns 70,267 shares of the company’s stock, valued at approximately $429,331.37. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,117,032 shares of company stock worth $6,559,891. Company insiders own 5.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Aratana Therapeutics (PETX) Stock Price” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-stock-price/1781372.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.